Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis

Pathophysiology and treatment of rheumatic disease

Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis

Pathophysiology and treatment of rheumatic disease

PREDICTORS OF DRUG-FREE REMISSION FOLLOWING TREATMENT WITH ABATACEPT (IN COMBINATION WITH METHOTREXATE OR AS MONOTHERAPY) IN EARLY RHEUMATOID ARTHRITIS

Pathophysiology and treatment of rheumatic disease

INDUCTION OF CLINICAL REMISSION FOLLOWED BY DRUG-FREE WITHDRAWAL WITH ABATACEPT COMBINATION AND MONOTHERAPY IN EARLY RA: RESULTS FROM THE AVERT STUDY OVER 18 MONTHS

Pathophysiology and treatment of rheumatic disease

Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis

Pathophysiology and treatment of rheumatic disease

Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis

Pathophysiology and treatment of rheumatic disease

Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis

Pathophysiology and treatment of rheumatic disease

Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis

Pathophysiology and treatment of rheumatic disease